Study for effectiveness of Unani drugs in white patches (vitiligo)

Phase 2

Completed

• Conditions: Health Condition 1: L80- VitiligoHealth Condition 2: L80- Vitiligo

• Registration Number: CTRI/2017/12/010998
• Lead Sponsor: Central Research Institute of Unani Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-07-25
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Patients of any sex in the age group between 18 and 40 Years Patients with NonSegmental Vitiligo (NSV), disease chronicity from 6 months to 2 years

Vitiligo involving more than 2% Body Surface Area (BSA)

Patients with less than 5 New Lesions in the last month

Patients with less than 15 lesions in the last 3 months

Patients who have not received systemic treatment within 4 weeks prior to study entry

Patients who have not received topical treatment within 2 weeks prior to study entry

Exclusion Criteria

Patients aged less than 18 years or more than 40 years

Pregnant or Lactating Women

Segmental Vitiligo (SV), liptip, or universal Vitiligo, or Vitiligo with leucotrichia

History of Photosensitivity/Photoexaggerated Dermatoses and Connective Tissue Diseases

Significant Pulmonary/Cardiovascular/Hepatorenal Dysfunction 6. Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (Cutaneous or Internal)

Patient not willing to attend treatment schedule regularly

Patients not having a suitable facility for sun exposure

Study & Design

• Study Type: Interventional
• Study Design: Not specified